To identify LSC-specific vulnerabilities, we characterized LSCs (CD34+ CD90– CD38–) and leukemic blasts (CD34+ CD90– CD38+) purified from a CEBPAN/C AML sample expressing both C/EBPα isoforms (Supplementary Fig. S6A–C). This evidence concerns the gene CD34 and acute myeloid leukemia.